Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006131 · ClinicalTrials.gov registry record · NA
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
A NA study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT00006131 is a NA study that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 66 participants.
The verdict
NCT00006131, a NA study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Compare the efficacy and safety of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster. II. Compare quality of life, pain, and medical resource utilization in patients treated with these 2 regimens.
Interventions
- DRUG Valacyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 1997-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006131
The ClinicalTrials.gov registry entry for NCT00006131 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Research Resources (NCRR), which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valacyclovir is the first listed.
NCT00006131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006131 about?
NCT00006131 is a clinical study titled "Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster". OBJECTIVES: I. Compare the efficacy and safety of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster. II. Compare quality of life, pain, and medical resource utilization in patients treated with these 2 regimens.
What is the current status of trial NCT00006131?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 1997-01.
What interventions are being tested in trial NCT00006131?
The interventions under investigation include: Valacyclovir (DRUG).
Who is sponsoring clinical trial NCT00006131?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.